An Innovative Multimodal Approach Combining Pathomics, Deep Learning, and Machine Learning for Classifying Histological Grades in Breast Cancer - Top-Institutions - MDSpire

An Innovative Multimodal Approach Combining Pathomics, Deep Learning, and Machine Learning for Classifying Histological Grades in Breast Cancer

  • By

  • Han Ding

  • Zheng Dong

  • March 12, 2026

  • 0 min

Share

Top Institutions in Pathology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Oncology
    • Computational Pathology
    • Machine Learning

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Cancer Research
    • Computational Oncology
    • Digital Pathology

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Biomedical Informatics
    • Pathology
    • Artificial Intelligence

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Pathology
    • Oncology
    • Machine Learning

  • #5

    University of Pittsburgh Medical Center (UPMC)
    University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, PA

    Key Differentiators

    • Digital Pathology
    • Breast Cancer
    • Machine Learning

Original Source(s)

An Innovative Multimodal Approach Combining Pathomics, Deep Learning, and Machine Learning for Classifying Histological Grades in Breast Cancer

  • by Han Ding, Zheng Dong

  • March 12, 2026

Related Content

Analysis of Regulatory Networks and Spatial Models Uncovers Mechanisms of Immune Evasion and Resistance in Estrogen Receptor-Positive Breast Cancer

Prognostic value of androgen receptor expression in ER-positive/HER2-negative breast cancer: evidence from a contemporary Chinese cohort

Retraction: Enhancer RNA SLIT2 inhibits bone metastasis of breast cancer through regulating P38 MAPK/c-Fos signaling pathway

  • May 7, 2026